Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Corporate VC Arm of Global Pharma Strategically Invests in Pre-Clinical Therapeutics in Areas Including Oncology, CNS, Immunology

27 Jan

A corporate venture capital arm of a global pharmaceutical company with a long operating history and an international footprint is actively seeking new investments. The parent organization operates worldwide and has expanded its global reach through strategic acquisitions in recent years. As part of its broader open innovation strategy, the parent organization actively pursues in- and out-licensing, early-stage partnerships, and strategic investments. The firm is responsible for executing strategic investments that support future partnering opportunities and help build the parent organization’s therapeutic pipeline. 

The firm was established a few years ago and operates from the United States. The firm manages an evergreen fund and focuses on pre-clinical startups with differentiated platforms and first-in-class programs in human therapeutics. The firm participates in Seed and Series A financing rounds, typically investing up to USD $5M initially, with the ability to invest up to USD $10M per company through follow-on capital. The firm is open to engaging with companies globally and has built a portfolio of more than a dozen investments, primarily across Europe and the United States. 

The firm targets pre-clinical to pre-IND, in-human therapeutics companies. Key areas of interest include oncology, neurology, immunology, and specialty disease areas such as fibrosis, endocrine disorders, and rare genetic diseases. The firm is modality-agnostic and considers small molecules, antibodies, nucleic acid-based therapies, and gene therapies. The firm does not invest in medical devices or diagnostics. 

The firm does not lead financing rounds. When co-investing or participating in syndicated rounds, the firm requires a board observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: VC Firm With Multiple Life Science-Focused Funds Seeks Early-Stage Therapeutics and AI-Enabled Technologies 

27 Jan

A venture capital platform associated with a leading global life sciences services provider manages multiple funds and focuses on investing in early-stage life science companies. The firm’s investment sweet spot spans from Seed through Series B stages. Initial check sizes typically range from USD $2–10M, with the ability to provide follow-on capital. The firm is open to both leading and co-investing and considers board or observer seats on a case-by-case basis. Backed by a major contract research organization, the firm leverages deep expertise in biotech research and development to deliver value beyond capital. 

The firm invests in biotech therapeutics, including small molecules, biologics, and drug discovery programs. Key areas of interest include oncology, immunology and inflammation, central nervous system diseases, and metabolic diseases, covering a broad range of commonly pursued indications. The firm evaluates opportunities from the pre-IND stage through Phase I clinical trials. In addition, the firm focuses on innovative AI-enabled healthcare opportunities with strong technological differentiation, including AI-integrated medical devices such as surgical robotics, brain–computer interfaces, and smart imaging systems, as well as AI-driven diagnostics, drug discovery acceleration platforms, and intelligent healthcare solutions designed to improve clinical efficiency and data-driven decision-making. 

The firm does not impose specific requirements regarding the composition of a company’s management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Early-Stage Focused Venture Fund Looks for Neuropsychiatric Opportunities from Pre-Seed to Series A Rounds

27 Jan

A venture capital firm focused on early-stage neuropsychiatric opportunities invests from Pre-Seed to Series A stages, with initial check sizes typically ranging from USD $50K to $1M. The firm is open to acting as the first institutional investor and may provide follow-on capital. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. The firm participates in both traditional equity rounds and SAFE agreements. While the firm primarily focuses on U.S.-based companies, the firm is also open to global opportunities. 

The firm invests in neuropsychiatric treatments and technologies aimed at improving mental health and general wellness. Areas of interest include psychedelic medicine, brain–computer interfaces, therapeutic platforms, precision diagnostics, and related technologies. For biotech opportunities, the firm prefers assets that are at or near the IND stage. For medtech opportunities, the firm is willing to engage earlier in the development process. 

The firm does not have strict requirements regarding management team composition but strongly prefers to work with founders who have prior pharmaceutical or biotech industry experience or a demonstrated track record of successful entrepreneurship. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based VC Firm With Strong Track Record Invests Up to €20M, Open to All Life Science & Healthcare Sectors 

16 Dec

The firm is a leading European venture capital firm investing in early- and growth-stage life science companies. The firm focuses on biotechnology, therapeutics, medical technology, diagnostics, digital health, and life science tools. The firm has a long track record of supporting innovative companies as they translate scientific breakthroughs into high-growth businesses. To date, the firm has invested in more than 60 life science companies, including multiple successful acquisitions by large pharmaceutical and medical technology companies. Initial investment sizes typically range from EUR 5–10 million, with the potential to invest up to EUR 20 million over the life of an investment. 

The firm invests primarily in Europe and selectively in the United States across five broad areas: therapeutics, medtech, diagnostics, digital health, and biotechnology and R&D tools. Within therapeutics, the firm focuses on early-stage companies with preclinical proof-of-concept data or programs approaching clinical entry, with a preference for highly innovative technology platforms and opportunities supported by early clinical data. In other sectors, the firm prefers companies with product candidates supported by strong intellectual property that are approaching regulatory approval or companies that have already launched a first product and achieved early market traction. 

From a company and management team perspective, the firm typically seeks a board seat and places strong emphasis on experienced, high-quality management teams. At the same time, the firm actively supports highly talented entrepreneurs and works closely with portfolio companies to help drive strategic, operational, and commercial execution. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office Firm Actively Seeking Early-Stage Life Science Technologies, With a Focus on Therapeutics and Drug Development 

16 Dec

A family office based in the United States invests across a wide range of sectors, including life science and healthcare. The firm primarily focuses on early-stage opportunities from Seed to Series A and may consider Series B investments on a case-by-case basis. Typical check sizes range from $100K to several million dollars, with the ability to invest additional capital by leveraging extended family resources. The firm prefers to co-invest in life science and healthcare transactions and may consider observer seats on a case-by-case basis. While the firm has a primary focus on the U.S. market, the firm does not have geographic restrictions and is open to global opportunities. 

Within life sciences and healthcare, the firm is open to evaluating a broad range of sectors and subsectors but has a primary focus on therapeutics assets and drug development. Areas of particular interest include cell and gene therapy programs targeting autoimmune diseases and oncology indications. 

The firm does not impose specific requirements on companies or management teams. The firm expects strong underlying science and compelling data supporting the targeted disease areas. The firm values founders who communicate effectively and consistently consider investor alignment and engagement. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm With US and Asia Offices Invests in Early-Stage Life Science Companies in Seed to Series A Rounds

16 Dec

A venture capital firm with offices in US and Asia primarily invests in Seed and Series A rounds, although the firm is not stage-focused or valuation sensitive, as the core focus is on return opportunities. The firm has a global investment team covering healthcare, consumer, enterprise, frontier, fintech, and more. The firm invests globally and typically acts as a co-investor, making approximately 2–5 new portfolio investments per quarter and 2–5 follow-on investments per quarter. Initial check sizes can be up to $1M USD. 

As a generalist investor within healthcare, the firm seeks transformative technologies that shape the future of the sector. 

The firm values founders with a clear vision to solve fundamental problems at the root cause level, emphasizing cost-effective solutions that can benefit large populations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Pharma With Investment Subsidiary Seeks Companies Developing Novel Drugs, Open to Various Modalities

16 Dec

The firm is a publicly listed pharmaceutical company with a global workforce and an international footprint that includes over 40 branches and subsidiaries worldwide. The firm’s core businesses are active pharmaceutical ingredients and generic drugs, while the firm is rapidly expanding into innovative drug development, including small molecules, biologics, and cell and gene therapies. A U.S.-based subsidiary operates as an integrated platform with research and development, manufacturing, and commercial capabilities, supplying generic drugs to major pharmacy chains, mass retailers, and grocery channels. 

Another subsidiary of the firm is responsible for equity investments and business development activities, including in-licensing and supplier or distributor partnerships, across both the China and U.S. markets. 

The firm is most interested in companies developing novel drugs across biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. From a development-stage perspective, the firm prefers programs at or before the NDA stage, including preclinical, Phase I, Phase II, Phase III, and NDA-ready assets. 

In addition to general equity investment and business development opportunities, the firm has particular interest in late-stage clinical assets that can be in-licensed and introduced into the China market, technologies that improve API manufacturing and production efficiency, and injectable drug products. The firm is also interested in distribution rights in China for both innovative and generic drugs, as well as distribution rights in the United States, primarily for generic drugs. 

From a company and management team perspective, the firm generally favors partners with strong scientific and technical capabilities, clear development and regulatory strategies, and high-quality data packages that support clinical and commercial potential. The firm typically values management teams that demonstrate execution capability, openness to strategic collaboration, and a willingness to engage in cross-border partnerships aligned with manufacturing, regulatory, and commercialization objectives. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

← Older Entries
Newer Entries →